Taipei, Taiwan, April 8, 2025 —Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company headquartered in Taiwan, has reported unaudited consolidated revenue of NT$1,592 million for March 2025. This represents a significant 65% month-over-month (MoM) increase and a 38% year-over-year (YoY) growth. For the first quarter of 2025, Lotus achieved revenue of NT$4,730 million, marking a 13% YoY growth.
In 1Q25, the Asian market showed strong performance, with a 12% YoY revenue increase, driven by exceptional growth in Thailand and Vietnam. The successful integration of Teva Pharma Thailand's operations and robust launch of Alpha Choay in Vietnam contributed to YoY growth of nearly 500% and 800%, respectively. Additionally, revenue from export markets rose by 14% YoY, fueled by lenalidomide sales in the U.S. and global markets, alongside a catch-up shipment of Buprenorphine/Naloxone in March (the generic version of Suboxone film).
During the first quarter, Lotus achieved several strategic milestones, including receiving approval from the Taiwan Food and Drug Administration (TFDA) for Adcirca (tadalafil), the only Class I therapy indicated for use with endothelin receptor antagonists (ERAs) as a first-line treatment for pulmonary arterial hypertension (PAH) in Taiwan. The company also submitted a potential first-to-file (FTF) application to the U.S. FDA for voclosporin, positioning itself for future market opportunities.
To support its growth and innovation, Lotus is expanding its R&D capabilities with the establishment of a new facility in Genome Valley, Hyderabad, India—a global hub for pharmaceutical research and development. This new center will focus on early-stage product development, leveraging the region's expertise and resources to accelerate FTF product launches and enhance market entry. This strategic investment strengthens Lotus's competitive position and underpins its commitment to driving long-term growth globally.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com